Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2010
Assuntos:
Commentary
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://ncbi.nlm.nih.gov/pubmed/20630094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-67
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares